Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency

Journal of Lipid Research

Volumn 53, Issue 9, 2012, Pages 1968-1978

  Campeau, Philippe M ^a   Astapova, Olga ^b   Martins, Rebecca ^c   Bergeron, Jean ^d   Couture, Patrick ^d   Hegele, Robert A ^c   Leff, Todd ^b   Gagné, Claude ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Anemia; Cytopenia; Peroxisome proliferator activated receptor gamma

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA SEQUENCE; DOWN REGULATION; FAMILY STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HETEROZYGOSITY; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIPID METABOLISM; LIPODYSTROPHY; MALE; METABOLIC SYNDROME X; MUSCLE DISEASE; MUSCLE METABOLISM; NEUROPATHY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; UPREGULATION;

ADULT; ANIMALS; FEMALE; GENES, DOMINANT; HETEROZYGOTE; HUMANS; LIPODYSTROPHY, FAMILIAL PARTIAL; MALE; MICE; MIDDLE AGED; MUTATION; NIH 3T3 CELLS; ORGAN SPECIFICITY; PHENOTYPE; PPAR GAMMA; RESPONSE ELEMENTS; TRANSCRIPTION, GENETIC;

EID: 84864844998     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P025437     Document Type: Article

References (36)

1. Hegele, R. A., T. R. Joy, S. A. Al-Attar, and B. K. Rutt. 2007. Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism. J. Lipid Res. 48: 1433-1444. (Pubitemid 47312005)
2. Mäkinen, V. P., M. Parkkonen, M. Wessman, P. H. Groop, T. Kanninen, and K. Kaski. 2005. High-throughput pedigree drawing. Eur. J. Hum. Genet. 13: 987-989. (Pubitemid 41131749)
3. Tremblay, A. J., H. Morrissette, J-M. Gagné, J. Bergeron, C. Gagné, and P. Couture. 2004. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with [beta]-quantification in a large population. Clin. Biochem. 37: 785-790. (Pubitemid 39141120)
4. Wallace, T. M., J. C. Levy, and D. R. Matthews. 2004. Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495. (Pubitemid 38680001)
5. Levey, A. S., J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130: 461-470. (Pubitemid 29135798)
6. Garenc, C., S. Aubert, J. Laroche, J. Bergeron, C. Gagne, F. Rousseau, and P. Julien. 2006. Gene polymorphisms in the Quebec population: a risk to develop hypertriglyceridemia. Biochem. Biophys. Res. Commun. 344: 588-596.
7. Cao, H., and R. A. Hegele. 2000. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum. Mol. Genet. 9: 109-112. (Pubitemid 30145295)
8. Hegele, R. A., H. Cao, C. Frankowski, S. T. Mathews, and T. Leff. 2002. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes. 51: 3586-3590. (Pubitemid 35403468)
9. Mahley, R. W., Y. Huang, and S. C. Rall, Jr. 1999. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J. Lipid Res. 40: 1933-1949. (Pubitemid 29523420)
10. Garg, A., M. Vinaitheerthan, P. T. Weatherall, and A. M. Bowcock. 2001. Phenotypic heterogeneity in patients with familial partial lipodystrophy (dunnigan variety) related to the site of missense mutations in lamin a/c gene. J. Clin. Endocrinol. Metab. 86: 59-65. (Pubitemid 32109776)
11. Garg, A. 2004. Acquired and inherited lipodystrophies. N. Engl. J. Med. 350: 1220-1234. (Pubitemid 38339366)
12. Spuler, S., T. Kalbhenn, J. Zabojszcza, F. K. H. van Landeghem, A. Ludtke, K. Wenzel, M. Koehnlein, M. Schuelke, L. Ludemann, and H. H. Schmidt. 2007. Muscle and nerve pathology in Dunnigan familial partial lipodystrophy. Neurology. 68: 677-683. (Pubitemid 46667815)
13. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350: 896-903. (Pubitemid 38252537)
14. Park, Y., B. D. Freedman, E. J. Lee, S. Park, and J. L. Jameson. 2003. A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. Diabetologia. 46: 365-377. (Pubitemid 36547592)
15. Stockner, T., H. Sterk, R. Kaptein, and A. M. J. J. Bonvin. 2003. Molecular dynamics studies of a molecular switch in the glucocorticoid receptor. J. Mol. Biol. 328: 325-334. (Pubitemid 36407578)
16. Li, G., and T. Leff. 2007. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes. Mol. Endocrinol. 21: 857-864. (Pubitemid 46984727)
17. Francis, G. A., G. Li, R. Casey, J. Wang, H. Cao, T. Leff, and R. A. Hegele. 2006. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet. 7: 3.
18. Greene, M. E., J. Pitts, M. A. McCarville, X. S. Wang, J. A. Newport, C. Edelstein, F. Lee, S. Ghosh, and S. Chu. 2000. PPARgamma: observations in the hematopoietic system. Prostaglandins Other Lipid Mediat. 62: 45-73.
19. Lefterova, M. I., D. J. Steger, D. Zhuo, M. Qatanani, S. E. Mullican, G. Tuteja, E. Manduchi, G. R. Grant, and M. A. Lazar. 2010. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. Mol. Cell. Biol. 30: 2078-2089.
20. Berria, R., L. Glass, A. Mahankali, Y. Miyazaki, A. Monroy, E. De Filippis, K. Cusi, E. Cersosimo, R. A. Defronzo, and A. Gastaldelli. 2007. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin. Pharmacol. Ther. 82: 275-281. (Pubitemid 47260544)
21. Nagasawa, E., Y. Abe, J. Nishimura, T. Yanase, H. Nawata, and K. Muta. 2005. Pivotal role of peroxisome proliferator-activated receptor gamma (PPARgamma) in regulation of erythroid progenitor cell proliferation and differentiation. Exp. Hematol. 33: 857-864. (Pubitemid 40982651)
22. Digman, C., A. K. Klein, and A. G. Pittas. 2005. Leukopenia and thrombocytopenia caused by thiazolidinediones. Ann. Intern. Med. 143: 465-466.
23. Saad, M. F., S. Greco, K. Osei, A. J. Lewin, C. Edwards, M. Nunez, and R. R. Reinhardt. 2004. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, doubleblind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care. 27: 1324-1329. (Pubitemid 38679978)
24. Clevidence, D. E., M. B. Juckett, and M. J. Lucarelli. 2009. Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone. WMJ. 108: 462-465.
25. Maaravi, Y., and J. Stessman. 2005. Mild, reversible pancytopenia induced by rosiglitazone. Diabetes Care. 28: 1536. (Pubitemid 40756737)
26. Naveiras, O., V. Nardi, P. L. Wenzel, P. V. Hauschka, F. Fahey, and G. Q. Daley. 2009. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 460: 259-263.
27. Chitteti, B. R., Y-H. Cheng, B. Poteat, S. Rodriguez-Rodriguez, W. S. Goebel, N. Carlesso, M. A. Kacena, and E. F. Srour. 2010. Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function. Blood. 115: 3239-3248.
28. Széles, L., D. Torocsik, and L. Nagy. 2007. PPARgamma in immunity and inflammation: cell types and diseases. Biochim. Biophys. Acta. 1771: 1014-1030. (Pubitemid 47202035)
29. Klotz, L., S. Burgdorf, I. Dani, K. Saijo, J. Flossdorf, S. Hucke, J. Alferink, N. Nowak, M. Beyer, et al. 2009. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med. 206: 2079-2089.
30. Setoguchi, K., Y. Misaki, Y. Terauchi, T. Yamauchi, K. Kawahata, T. Kadowaki, and K. Yamamoto. 2001. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J. Clin. Invest. 108: 1667-1675. (Pubitemid 33144877)
31. Schmidt, M. V., B. Brune, and A. von Knethen. 2010. The nuclear hormone receptor PPARgamma as a therapeutic target in major diseases. ScientificWorldJournal. 10: 2181-2197.
32. Lefstin, J. A., and K. R. Yamamoto. 1998. Allosteric effects of DNA on transcriptional regulators. Nature. 392: 885-888. (Pubitemid 28232051)
33. Collins, G. A., and W. P. Tansey. 2006. The proteasome: a utility tool for transcription? Curr. Opin. Genet. Dev. 16: 197-202. (Pubitemid 43376068)
34. Kilroy, G. E., X. Zhang, and Z. E. Floyd. 2009. PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal. Obesity (Silver Spring). 17: 665-673.
35. Nielsen, R., T. A. Pedersen, D. Hagenbeek, P. Moulos, R. Siersbaek, E. Megens, S. Denissov, M. Borgesen, K. J. Francoijs, S. Mandrup, et al. 2008. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 22: 2953-2967.
36. De Benoist, B., E. McLean, I. Egli, and M. Cogswell. 2008. Worldwide prevalence of anaemia 1993-2005, WHO Global Database on Anemia. In. World Health Organization, Geneva. 41.